Contribute Try STAT+ Today

A former Sanofi-Genzyme employee is accusing the company of inappropriately seeking confidential patient information, as part of a lawsuit alleging her wrongful termination.

The lawsuit, filed in late December in Massachusetts federal court, says the former Sanofi-Genzyme employee made a formal, internal complaint about the inappropriate request for confidential information, after which she experienced “harassment” and “discrimination … in retaliation for the reports she made about [her manager’s] efforts to obtain confidential patient data.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • This is the tip of the iceberg people. That confidential data is very valuable, and it has already been collected adncollated form millions of Americans. All of this data is sold to the highest bidder, and has had no positive benefit for anyone. People should be asking, Who is buying this data. The big Elephant in the room……

Comments are closed.